inhibitor
-
S*BIO to initiate global phase 3 clinical trials of its novel JAK2 inhibitor
S*BIO explores partnering opportunities for advancement of its JAK2 program.
inhibitor | 25 October 2011
-
Dr Reddy's starts phase 2 study with CETP inhibitor in dyslipidemia patients
Dr Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type 2 dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.
inhibitor | 05 September 2011
-
Pharmacyclics collaborates with National Cancer Institute to develop Btk inhibitor
Pharmacyclics, Inc announced the signing of a five-year cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765. This is a first-in-class, small molecule inhibitor…
inhibitor | 10 August 2011
-
Kowa reports efficacy and safety of Rho kinase inhibitor
Kowa Company Ltd announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension (K-115). The results were presented as three posters at The Association for Research in Vision and Ophtha…
inhibitor | 11 May 2011
-
4SC, Yakult Honsha announce license agreement for oral inhibitor in Japan
4SC AG and Yakult Honsha Co Ltd announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialization of resminostat in Japan. Resminostat, an oral, pan-histone deacetylase (HDAC) inhibitor, is currently being …
inhibitor | 15 April 2011
-
S*BIO initiates phase 2 clinical trial of its JAK2 inhibitor
S*BIO Pte Ltd announced that it has dosed the first 10 patients in a phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the US and Canada for the treatment of advanced lymphoid malignancies. This multi-center, open-label, study is design…
inhibitor | 14 April 2011
-
Roche announces positive pivotal phase 2 results for Hedgehog pathway inhibitor
Roche announced that a pivotal phase 2 clinical study of its investigational Hedgehog pathway inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating…
inhibitor | 21 March 2011
-
S*BIO presents novel dual inhibitor at American Association of Cancer Research conference
S*BIO Pte Ltd announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models. I…
inhibitor | 08 March 2011
-
S*BIO and Onyx Pharmaceuticals Expand Collaboration for JAK2 Inhibitors
S*BIO and Onyx Pharmaceuticals have announced the expansion of their development collaboration and option and license commercialization agreement for the former’s JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively…
inhibitor | 19 May 2010
-
S*Bio: Jak2 Inhibitor Demonstrates Safety in Studies for Myeloproliferative Disorder
S*BIO has announced data presentations on its oral JAK2 inhibitor, SB1518. Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) …
inhibitor | 09 December 2009
